ArunA has built a comprehensive intellectual property portfolio encompassing key aspects of exosome-based therapeutics.
Coupled with proprietary manufacturing methods, the company is set to develop transformational therapeutics across a range of CNS and neurodegenerative disorders.
We are actively seeking partnerships in the stroke and neural degenerative disease space, and also seeking partners in drug delivery and gene therapy.
Novel non-cellular biologic approach
Exploiting complex pathophysiologic pathways to address acute and chronic neurologic conditions
Proven neural protection and anti-inflammatory activity
Poised to advance multiple indications into clinical development
Consistent, scalable exosome manufacturing process
Strong science platform with continuing leadership by Dr. Steven Stice
Treatment greatly reduces hemorrhaging within 24 hours post injury
To discuss a potential partnership with ArunA, please contact Al Medwar at email@example.com.